Search Results - malaria+(plasmodium+sp.)

6 Results

Sort By:

Compounds That Treat Malaria and Prevent Malaria Transmission

Malaria is the single leading cause of death, especially among children, in the developing world. Malaria is caused by infection with parasites of the genus Plasmodium, transmitted by mosquitos. In addition to transmission, vital steps in the parasite lifecycle occur in the mosquito host. The invention offered for licensing relates to therapeutic compounds...

Published: 7/25/2024 | Inventor(s): Jing Yuan, Sittiporn Pattaradilokrat, Ruili Huang, Ronald Johnson, Dipak Raj, Xin-zhuan Su

Keywords(s): ANTIMALARIAL, DB2XXX, DBXXXX, Discovery, DRUGS, DXXXXX, Malaria (Plasmodium sp.), Potential, UBXXXX, UXXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases

Erythroid Progenitor Cell Line for Hematological Disease Applications

Plasmodium vivax (malaria) is a significant health concern in many parts of Asia, Latin America, North Africa, and the Middle East. There is a lack of continuous culture systems for this pathogen. The subject technology is an erythroid progenitor continuous cell line (termed CD36E) identified by erythroid markers CD36, CD33, CD44, CD71, CD235, and...

Published: 7/25/2024 | Inventor(s): Ning Zhi, Neal Young, Susan Wong

Keywords(s): &, Blod, Blood, CD36E, Cell, Cells, continuous, DDXXXX, DISEASES, DXXXXX, Erythroid, Involving, Line, Malaria, Malaria (Plasmodium sp.), Patent Category - Biotechnology, PLASMODIUM, Potential, PRECURSORS, Progenitor, RED, Spp., STUDIES, termed, USES

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Research Materials, TherapeuticArea > Infectious Disease

Vaccines Against Malarial Diseases

The invention offered for licensing is in the field of use of vaccines for malaria. The invention provides gene sequences encoding an erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic...

Published: 7/25/2024 | Inventor(s): David Narum

Keywords(s): DC2XXX, DCXXXX, DXXXXX, GENES, Malaria, Malaria (Plasmodium sp.), MALARIAL, Methods, proteins, SACGHS DNA Patent Initial Set, Synthetic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

A Novel Treatment for Malarial Infections

The inventions described herein are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to...

Published: 7/25/2024 | Inventor(s): Sanjay Desai

Keywords(s): Anion, ANTAGONISTS, ANTIMALARIAL, BBXXXX, BCXXXX, CHANNEL, DB2XXX, DBXXXX, Development, DRUG, DXXXXX, LEAD, Malaria, Malaria (Plasmodium sp.), MOLECULES, Plasmodial, Surface

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Transmission-Blocking Vaccine Against Malaria (1)

A transmission blocking vaccine developed against malaria contains a recombinant virus, which encodes a unique portion of the sexual stage surface antigen of Plasmodium falciparum (referred to as Pfs25), or the Pfs25 protein purified from infected host cells. Mice inoculated with the recombinant virus developed antibodies capable of blocking transmission...

Published: 7/25/2024 | Inventor(s): David Kaslow

Keywords(s): DC2XXX, DCXXXX, DXXXXX, Malaria, Malaria (Plasmodium sp.)

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Anti-Plasmodium Compositions and Methods of Use

This invention describes methods and compositions of peptides that inhibit the binding of Plasmodium falciparum (P. falciparum) to erythrocytes. Malarial parasites enter the red blood cell through several erythrocyte receptors, each being specific for a given species of Plasmodia. For P. falciparum, the erythrocyte binding antigen (EBA-175) is the...

Published: 7/25/2024 | Inventor(s): David Narum

Keywords(s): DA2XXX, DAXXXX, DB2XXX, DBXXXX, DC2XXX, DCXXXX, DXXXXX, Malaria, Malaria (Plasmodium sp.)

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines